These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 33172501)

  • 1. Prognosis prediction model for conversion from mild cognitive impairment to Alzheimer's disease created by integrative analysis of multi-omics data.
    Shigemizu D; Akiyama S; Higaki S; Sugimoto T; Sakurai T; Boroevich KA; Sharma A; Tsunoda T; Ochiya T; Niida S; Ozaki K
    Alzheimers Res Ther; 2020 Nov; 12(1):145. PubMed ID: 33172501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of potential blood biomarkers for early diagnosis of Alzheimer's disease through RNA sequencing analysis.
    Shigemizu D; Mori T; Akiyama S; Higaki S; Watanabe H; Sakurai T; Niida S; Ozaki K
    Alzheimers Res Ther; 2020 Jul; 12(1):87. PubMed ID: 32677993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA Expression Signature in Mild Cognitive Impairment Due to Alzheimer's Disease.
    De Felice B; Montanino C; Oliva M; Bonavita S; Di Onofrio V; Coppola C
    Mol Neurobiol; 2020 Nov; 57(11):4408-4416. PubMed ID: 32737762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival Analysis in Cognitively Normal Subjects and in Patients with Mild Cognitive Impairment Using a Proportional Hazards Model with Extreme Gradient Boosting Regression.
    Khajehpiri B; Moghaddam HA; Forouzanfar M; Lashgari R; Ramos-Cejudo J; Osorio RS; Ardekani BA;
    J Alzheimers Dis; 2022; 85(2):837-850. PubMed ID: 34864679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validating the role of the Australian National University Alzheimer's Disease Risk Index (ANU-ADRI) and a genetic risk score in progression to cognitive impairment in a population-based cohort of older adults followed for 12 years.
    Andrews SJ; Eramudugolla R; Velez JI; Cherbuin N; Easteal S; Anstey KJ
    Alzheimers Res Ther; 2017 Mar; 9(1):16. PubMed ID: 28259165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A parameter-efficient deep learning approach to predict conversion from mild cognitive impairment to Alzheimer's disease.
    Spasov S; Passamonti L; Duggento A; Liò P; Toschi N;
    Neuroimage; 2019 Apr; 189():276-287. PubMed ID: 30654174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APOEɛ4-TOMM40L Haplotype Increases the Risk of Mild Cognitive Impairment Conversion to Alzheimer's Disease.
    Cardoso R; Lemos C; Oliveiros B; Almeida MR; Baldeiras I; Pereira CF; Santos A; Duro D; Vieira D; Santana I; Oliveira CR
    J Alzheimers Dis; 2020; 78(2):587-601. PubMed ID: 33016906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment.
    Lacour A; Espinosa A; Louwersheimer E; Heilmann S; Hernández I; Wolfsgruber S; Fernández V; Wagner H; Rosende-Roca M; Mauleón A; Moreno-Grau S; Vargas L; Pijnenburg YA; Koene T; Rodríguez-Gómez O; Ortega G; Ruiz S; Holstege H; Sotolongo-Grau O; Kornhuber J; Peters O; Frölich L; Hüll M; Rüther E; Wiltfang J; Scherer M; Riedel-Heller S; Alegret M; Nöthen MM; Scheltens P; Wagner M; Tárraga L; Jessen F; Boada M; Maier W; van der Flier WM; Becker T; Ramirez A; Ruiz A
    Mol Psychiatry; 2017 Jan; 22(1):153-160. PubMed ID: 26976043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Subtyping of Mild Cognitive Impairment Based on Genetic Polymorphism and Gene Expression.
    Li HT; Yuan SX; Wu JS; Zhang XZ; Liu Y; Sun X
    J Prev Alzheimers Dis; 2021; 8(2):224-233. PubMed ID: 33569571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.
    Sala I; Illán-Gala I; Alcolea D; Sánchez-Saudinós MB; Salgado SA; Morenas-Rodríguez E; Subirana A; Videla L; Clarimón J; Carmona-Iragui M; Ribosa-Nogué R; Blesa R; Fortea J; Lleó A
    J Alzheimers Dis; 2017; 58(3):909-918. PubMed ID: 28527215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-129-5p as a biomarker for pathology and cognitive decline in Alzheimer's disease.
    Han SW; Pyun JM; Bice PJ; Bennett DA; Saykin AJ; Kim SY; Park YH; Nho K
    Alzheimers Res Ther; 2024 Jan; 16(1):5. PubMed ID: 38195609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gender, apolipoprotein E genotype, and mesial temporal atrophy: 2-year follow-up in patients with stable mild cognitive impairment and with progression from mild cognitive impairment to Alzheimer's disease.
    Spampinato MV; Langdon BR; Patrick KE; Parker RO; Collins H; Pravata' E;
    Neuroradiology; 2016 Nov; 58(11):1143-1151. PubMed ID: 27590747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Grading Biomarker for the Prediction of Conversion From Mild Cognitive Impairment to Alzheimer's Disease.
    Tong T; Gao Q; Guerrero R; Ledig C; Chen L; Rueckert D; Initiative ADN
    IEEE Trans Biomed Eng; 2017 Jan; 64(1):155-165. PubMed ID: 27046891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Joint Effect of ABCA7 rs4147929 and Body Mass Index on Progression from Mild Cognitive Impairment to Alzheimer's Disease: The Shanghai Aging Study.
    Xi J; Ding D; Zhao Q; Liang X; Zheng L; Guo Q; Hong Z; Fu H; Xu J; Xiao Q
    Curr Alzheimer Res; 2020; 17(2):185-195. PubMed ID: 32183673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of candidate mRNAs and miRNAs as biomarkers for mild cognitive impairment and Alzheimer's disease.
    Qin H; Hu C; Zhao X; Tian M; Zhu B
    Int J Neurosci; 2023 Jan; 133(1):89-102. PubMed ID: 33541173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower Serum Calcium as a Potentially Associated Factor for Conversion of Mild Cognitive Impairment to Early Alzheimer's Disease in the Japanese Alzheimer's Disease Neuroimaging Initiative.
    Sato K; Mano T; Ihara R; Suzuki K; Tomita N; Arai H; Ishii K; Senda M; Ito K; Ikeuchi T; Kuwano R; Matsuda H; Iwatsubo T; Toda T; Iwata A;
    J Alzheimers Dis; 2019; 68(2):777-788. PubMed ID: 30814351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and validation of endogenous control miRNAs in plasma samples for normalization of qPCR data for Alzheimer's disease.
    Dakterzada F; Targa A; Benítez ID; Romero-ElKhayat L; de Gonzalo-Calvo D; Torres G; Moncusí-Moix A; Huerto R; Sánchez-de-la-Torre M; Barbé F; Piñol-Ripoll G
    Alzheimers Res Ther; 2020 Dec; 12(1):163. PubMed ID: 33278902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of Butyrylcholinesterase in Progression of Mild Cognitive Impairment to Alzheimer's Disease.
    Gabriel AJ; Almeida MR; Ribeiro MH; Carneiro D; Valério D; Pinheiro AC; Pascoal R; Santana I; Baldeiras I
    J Alzheimers Dis; 2018; 61(3):1097-1105. PubMed ID: 29254094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment.
    Shen Y; Wang H; Sun Q; Yao H; Keegan AP; Mullan M; Wilson J; Lista S; Leyhe T; Laske C; Rujescu D; Levey A; Wallin A; Blennow K; Li R; Hampel H
    Biol Psychiatry; 2018 Mar; 83(5):447-455. PubMed ID: 28359566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.